
PharmFilm®

Delivering Therapeutic and Clinical Advances With PharmFilm® Technology

With proprietary PharmFilm® technology, Aquestive Therapeutics, Inc. helps solve therapeutic problems and meaningfully improves the lives of people with critical and complex conditions who face barriers to using important medications. Our drug-by-drug approach harnesses the power of our versatile, high-performing drug delivery technology to achieve target product profiles and clinical improvement goals.



Multiple routes of administration optimize delivery and address complex dosing challenges



BUCCAL

The greater surface area and reduced salivary flow facilitate increased absorption without the need for water or liquids. PharmFilm® allows for active diffusion through the oral mucosa and direct entry into the bloodstream with a controlled release profile aided by an engineered retention time along with a controlled microenvironment at the mucosal interface.



LINGUAL

Rapid disintegration, controlled release, and bioequivalence to other oral dosage forms allow for reduced negative gastrointestinal effects, retention of therapeutic efficacy, and the opportunity to lower API doses when compared to other conventional oral delivery forms.



SUBLINGUAL

Dissolves quickly and is absorbed transmucosally into the blood stream for rapid uptake and onset of action.

Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to standard of care therapies with invasive administration.

Depending on the active pharmaceutical ingredients (APIs), PharmFilm® provides three possible routes of administration. By optimizing a drug's pharmacokinetic profile, our Development Services team can optimize absorption and onset of action, potentially reduce drug exposure, and provide for easy, convenient, and accurate dosing. PharmFilm® eliminates the need for mixing, swallowing, and chewing and comes in a variety of flavors, which make it more agreeable to patients and caregivers and increases compliance.¹

Strategic Collaborations and Proprietary Technology Create Optimized Treatments

Aquestive has established more than 10 proprietary and pipeline collaborations over 12 years. These strategic collaborations—both in-licensed and out-licensed—leverage our scientific and regulatory expertise and integrated capabilities to test and deliver treatments optimized using PharmFilm® technology. It all starts with our Formulation Engineering team, who uniquely tailors the features of this technology according to the API's chemical structure to achieve the target profile for the product.







Learn what is possible with PharmFilm[®] technology

Visit **aquestive.com/innovative-drug-delivery-pharmfilm/** to see the differentiating opportunities with PharmFilm[®] and what optimized treatment can do for patients.

Reference: 1. Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015;(75):2-9.





© 2020 Aquestive Therapeutics, Inc. PharmFilm[®] and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All rights reserved. June 2020.